| A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer (NCT05227664) | Akeso | 2022-03-23 |
| P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC . (NCT05008510) | Veru Inc. | 2021-12-30 |
| Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (NCT05101096) | Gilead Sciences | 2021-10-20 |
| Olinvacimab With Pembrolizumab in Patients With mTNBC (NCT04986852) | PharmAbcine | 2021-09-30 |
| Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer (NCT04739670) | Peter MacCallum Cancer Centre, Australia | 2021-03-01 |
| Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments (NCT04454437) | Gilead Sciences | 2020-10-23 |
| A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer (NCT04149444) | AHS Cancer Control Alberta | 2020-02-01 |
| Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer (NCT04111510) | Yale University | 2019-12-23 |
| Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile (NCT04250818) | Texas Tech University Health Sciences Center, El Paso | 2019-07-02 |
| Leflunomide in Previously Treated Metastatic Triple Negative Cancers (NCT03709446) | Joseph Sparano | 2019-04-16 |
| Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer (NCT05089643) | Chinese Academy of Medical Sciences | 2019-04-11 |
| Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer (NCT03577743) | Assiut University | 2018-07-01 |
| Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases (NCT03256344) | Amgen | 2018-03-19 |
| To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. (NCT03330847) | AstraZeneca | 2018-03-07 |
| S 81694 Plus Paclitaxel in Metastatic Breast Cancer (NCT03411161) | Institut de Recherches Internationales Servier | 2018-01-04 |
| SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (NCT03004183) | The Methodist Hospital Research Institute | 2017-07-01 |
| Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer (NCT03121352) | Case Comprehensive Cancer Center | 2017-05-19 |
| Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer (NCT03055312) | Sun Yat-sen University | 2016-12-20 |
| L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (NCT02834403) | The Methodist Hospital Research Institute | 2016-11-01 |
| Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) (NCT02555657) | Merck Sharp & Dohme LLC | 2015-10-13 |
| Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer (NCT02158507) | University of Alabama at Birmingham | 2014-09-04 |
| Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (NCT01936961) | Western Regional Medical Center | 2013-06-01 |
| Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer (NCT01238952) | Nippon Kayaku Co., Ltd. | 2010-07-01 |